An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral

Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Julander, Justin G., Demarest, James F., Taylor, Ray, Gowen, Brian B., Walling, Dennis M., Mathis, Amanda, Babu, Y.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483777/
https://www.ncbi.nlm.nih.gov/pubmed/34551346
http://dx.doi.org/10.1016/j.antiviral.2021.105180
_version_ 1784577182733959168
author Julander, Justin G.
Demarest, James F.
Taylor, Ray
Gowen, Brian B.
Walling, Dennis M.
Mathis, Amanda
Babu, Y.S.
author_facet Julander, Justin G.
Demarest, James F.
Taylor, Ray
Gowen, Brian B.
Walling, Dennis M.
Mathis, Amanda
Babu, Y.S.
author_sort Julander, Justin G.
collection PubMed
description Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation in several phase I clinical trials, including against severe acute respiratory syndrome coronavirus 2, and as a medical countermeasure for the treatment of Marburg virus disease.
format Online
Article
Text
id pubmed-8483777
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-84837772021-10-01 An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral Julander, Justin G. Demarest, James F. Taylor, Ray Gowen, Brian B. Walling, Dennis M. Mathis, Amanda Babu, Y.S. Antiviral Res Article Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation in several phase I clinical trials, including against severe acute respiratory syndrome coronavirus 2, and as a medical countermeasure for the treatment of Marburg virus disease. The Authors. Published by Elsevier B.V. 2021-11 2021-09-20 /pmc/articles/PMC8483777/ /pubmed/34551346 http://dx.doi.org/10.1016/j.antiviral.2021.105180 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Julander, Justin G.
Demarest, James F.
Taylor, Ray
Gowen, Brian B.
Walling, Dennis M.
Mathis, Amanda
Babu, Y.S.
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
title An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
title_full An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
title_fullStr An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
title_full_unstemmed An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
title_short An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
title_sort update on the progress of galidesivir (bcx4430), a broad-spectrum antiviral
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483777/
https://www.ncbi.nlm.nih.gov/pubmed/34551346
http://dx.doi.org/10.1016/j.antiviral.2021.105180
work_keys_str_mv AT julanderjusting anupdateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT demarestjamesf anupdateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT taylorray anupdateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT gowenbrianb anupdateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT wallingdennism anupdateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT mathisamanda anupdateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT babuys anupdateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT julanderjusting updateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT demarestjamesf updateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT taylorray updateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT gowenbrianb updateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT wallingdennism updateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT mathisamanda updateontheprogressofgalidesivirbcx4430abroadspectrumantiviral
AT babuys updateontheprogressofgalidesivirbcx4430abroadspectrumantiviral

Ejemplares similares